Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity of 3 Lots of GSK Biologicals' Novel Adjuvanted Hepatitis B Vaccine, Administered According to a 2 Dose Schedule, and Engerix™-B Administered According to a 3 Dose Schedule to Healthy Volunteers ≥ 15 Years of Age

NCT00696917 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00696917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00696917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity of 3 Lots of GSK Biologicals' Novel Adjuvanted Hepatitis B Vaccine, Administered According to a 2 Dose Schedule, and Engerix™-B Administered According to a 3 Dose Schedule to Healthy Volunteers ≥ 15 Years of Age
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
April 30, 1999
Completion date
Not reported
Enrollment
1,303 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b